Gliomas represent the most common solid tumor of the nervous system, and can occur as both low and high-grade tumors. Current risk stratification and treatment approaches rely heavily on the morphological classification of gliomas whereby low-grade gliomas have an excellent prognosis, particularly pilocytic astrocytomas, while high-grade gliomas have a poor prognosis. The past decade has witnessed a dramatic increase in scholars’ knowledge of the biology of pediatric low-grade gliomas particularly through the advent of integrated genomics and next generation sequencing. Indeed, many of these biological advances are changing treatment paradigms, particularly in low-grade gliomas, where rationale targeted therapies are currently being explored in clinical trials. In this review the authors summarize the current approach to pediatric low grade gliomas and outline the biological advances over the past 10 years, which will be driving the next generation of clinical trials.
LouisDNOhgakiHWiestlerOD. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.
2.
LouisDNPerryABurgerP. International Society of Neuropathology—Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014;24(5):429–435.
3.
TolaMRCasettaIGranieriE. Intracranial gliomas in Ferrara, Italy, 1976 to 1991. Acta Neurol Scand. 1994;90(5):312–317.
4.
OstromQTGittlemanHLiaoP. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncol. 2014;16(suppl 4):1–63.
5.
BilginerBNarinFOguzKKUzunSSoylemezogluFAkalanN. Benign cerebellar pilocytic astrocytomas in children. Turk Neurosurg. 2011;21(1):22–26.
6.
LoteKStenwigAESkullerudKHirschbergH. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer. 1998;34(1):98–102.
7.
RondinelliPIOsorioCACohenMPNovaesPE. Unusual dissemination patterns of low-grade astrocytomas in childhood. Arq Neuropsiquiatr. 2008;66(1):45–49.
8.
CivitelloLAPackerRJRorkeLBSiegelKSuttonLNSchutL. Leptomeningeal dissemination of low-grade gliomas in childhood. Neurol. 1988;38(4):562–566.
9.
PerilongoGGarreMLGiangasperoF. Low-grade gliomas and leptomeningeal dissemination: a poorly understood phenomenon. Childs Nerv Syst. 2003;19(4):197–203.
10.
RicciPEDunganDH. Imaging of low- and intermediate-grade gliomas. Semin Radiat Oncol. 2001;11(2):103–112.
11.
StrongJAHattenHPJrBrownMT. Pilocytic astrocytoma: correlation between the initial imaging features and clinical aggressiveness. AJR Am J Roentgenol. 1993;161(2):369–372.
12.
LeeYYVan TasselPBrunerJMMoserRPShareJC. Juvenile pilocytic astrocytomas: CT and MR characteristics. AJR Am J Roentgenol. 1989;152(6):1263–1270.
13.
PanigrahyABlumlS. Neuroimaging of pediatric brain tumors: from basic to advanced magnetic resonance imaging (MRI). J Child Neurol. 2009;24(11):1343–1365.
14.
BignerSHMcLendonREFuchsHMcKeeverPEFriedmanHS. Chromosomal characteristics of childhood brain tumors. Cancer Genet Cytogenet. 1997;97(2):125–134.
15.
SmithJSPerryABorellTJ. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18(3):636–645.
16.
NakamuraMShimadaKIshidaE. Molecular pathogenesis of pediatric astrocytic tumors. Neuro-oncol. 2007;9(2):113–123.
17.
PollackIFFinkelsteinSDBurnhamJ. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res. 2001;61(20):7404–7407.
18.
YanHParsonsDWJinG. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773.
19.
JacobKAlbrechtSSollierC. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer. 2009;101(4):722–733.
20.
JonesDTKocialkowskiSLiuL. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673–8677.
21.
ForshewTTatevossianRGLawsonAR. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol. 2009;218(2):172–181.
22.
LinARodriguezFJKarajannisMA. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549: BRAF fusion variants. J Neuropathol Exp Neurol. 2012;71(1):66–72.
23.
JonesDTKocialkowskiSLiuLPearsonDMIchimuraKCollinsVP. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549: BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene. 2009;28(20):2119–2123.
24.
CinHMeyerCHerrR. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011;121(6):763–774.
JonesDTHutterBJagerN. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45(8):927–932.
27.
PfisterSJanzarikWGRemkeM. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008;118(5):1739–1749.
28.
SievertAJJacksonEMGaiX. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 2009;19(3):449–458.
29.
GronychJKorshunovABageritzJ. An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest. 2011;121(4):1344–1348.
30.
HawkinsCWalkerEMohamedN. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res. 2011;17(14):4790–4798.
31.
MoritaHNagaiR. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365(15):1448, author reply 50.
32.
Farina-SarasquetaAvan LijnschotenGMoerlandE. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21(12):2396–2402.
33.
SchindlerGCapperDMeyerJ. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397–405.
34.
HorbinskiCNikiforovaMNHagenkordJMHamiltonRLPollackIF. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro-oncol. 2012;14(6):777–789.
35.
RodriguezFJPerryAGutmannDH. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol. 2008;67(3):240–249.
36.
BallesterRMarchukDBoguskiM. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 1990;63(4):851–859.
37.
YunoueSTokuoHFukunagaK. Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras. J Biol Chem. 2003;278(29):26958–26969.
38.
Khuong-QuangDABuczkowiczPRakopoulosP. K27 M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012;124(3):439–447.
39.
SchwartzentruberJKorshunovALiuXY. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–231.
40.
SturmDWittHHovestadtV. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425–437.
41.
FontebassoAMPapillon-CavanaghSSchwartzentruberJ. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014;46(5):462–466.
42.
WuGBroniscerAMcEachronTA. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44(3):251–253.
43.
YuenBTKnoepflerPS. Histone H3.3 mutations: a variant path to cancer. Cancer Cell. 2013;24(5):567–574.
44.
WisoffJHSanfordRAHeierLA. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s Oncology Group. Neurosurg. 2011;68(6):1548–1554, discussion 1554-1555.
45.
BeneschMEderHGSovinzP. Residual or recurrent cerebellar low-grade glioma in children after tumor resection: is re-treatment needed? A single center experience from 1983 to 2003. Pediatr Neurosurg. 2006;42(3):159–164.
46.
AterJLZhouTHolmesE. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(21):2641–2647.
47.
BouffetEJakackiRGoldmanS. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30(12):1358–1363.
48.
AveryRAHwangEIJakackiRIPackerRJ. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol. 2014;132(1):111–114.
49.
FlahertyKTInfanteJRDaudA. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–1703.
50.
KarajannisMALegaultGFisherMJ. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-oncol. 2014;16(10):1408–1416.
51.
BandopadhayayPBergtholdGLondonWB. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014;61(7):1173–1179.
